Vortioxetine Improved Depressive State In Parkinson’s Disease

Reiji Yoshimura 1, Atsuko Ikenouchi 1, Naomichi Okamoto 1, Yuki Konishi 1

1. Psychiatry, University of Occupational and Environmental Health, Kitakyushu, JPN

Corresponding author: Reiji Yoshimura, yoshi621@med.uoeh-u.ac.jp

Abstract

We report the case of a 67-year-old Japanese Parkinson’s disease (PD) patient with depression who was successfully treated with vortioxetine. The patient’s PD was being treated with levodopa (100 mg/day). As improvement was noted in PD symptoms, levodopa was continued. Subsequently, she was referred to our department due to worsening of her depressive symptoms, including depressed mood, anhedonia, decreased energy, decreased concentration, decreased motivation, insomnia, hopelessness, and worthlessness. The patient did not respond to paroxetine and escitalopram. Finally, vortioxetine improved her depressive state without worsening PD.

Categories: Psychiatry
Keywords: vortioxetine, depression, parkinson’s disease, case report, levodopa

Introduction

Parkinson’s disease (PD) is one of the most common and severe movement disorders globally, affecting about 1% of adults older than 60 years [1]. PD results from the loss of dopamine neurons in the substantia nigra, and its cause is not yet elucidated in most individuals [1]. Depression is common among PD patients. It is generally accepted that clinically significant depressive disturbances occur in 40-50% of patients with PD and affect various clinical aspects of the disease [2]. In addition to causing inherent mood distress, depressive disorders negatively impact patients’ quality of life, motor and cognitive deficits, and functional disability. For patients, these neuropsychiatric symptoms are often more problematic and distressing than the motor symptoms of PD. A recent network meta-analysis demonstrated that selective serotonin reuptake inhibitors (SSRIs), serotonin noradrenaline reuptake inhibitors (SNRIs), and tricyclic antidepressants (TCAs) were efficacious against depression among PD patients and improved their activities of daily living and motor functions [3-6]. However, adverse effects have been reported including extrapyramidal symptoms [7,8]. Here, we report the case of a PD patient with depressive disorder due to another medical condition based on the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5), who was successfully treated with vortioxetine but was unresponsive to paroxetine and escitalopram without worsening the extrapyramidal symptoms of PD.

Case Presentation

A 67-year-old Japanese woman was referred to a general hospital and was diagnosed with PD after examination by a neurologist. Her clinical presentation included masking of facial expressions, decreased eye blink rate, bradykinesia, and cogwheel rigidity. She was treated with levodopa (100 mg/day). As her PD improved, levodopa was continued. Subsequently, she was referred to our department at the University of Occupational and Environmental Health, Japan, due to worsening of her depressive symptoms a month before, including depressed mood, anhedonia, decreased energy, decreased concentration, decreased motivation, insomnia, hopelessness, and worthlessness without any particular life events or stressors. Moreover, she had never experienced previous depressive episodes. In particular, her anhedonia and decreased energy, concentration, and motivation were severe. Her Mini-Mental State Examination score was 30/30, indicating no specific cognitive impairment. Magnetic resonance imaging revealed no abnormality. Her endocrinologic examination was also normal. She was diagnosed with depressive disorder due to another medical condition according to the DSM-5. Her Hamilton Rating Scale for Depression (HAM-D) score was 26. Her depressive symptoms did not improve with paroxetine (40 mg/day) for four weeks or venlafaxine (100 mg/day) for four weeks. The mean HAM-D score was 24. Venlafaxine was switched to escitalopram, with the dose increased to 20 mg/day. On switching the medication, her depressive symptoms slightly improved. The HAM-D score reduced to 19 after six weeks of escitalopram administration. Further improvement was observed after escitalopram treatment for six weeks. As her depressive symptoms did not respond to treatment with typical SSRIs or SNRIs, she was started on vortioxetine (10 mg/day). Vortioxetine dosage was increased to 20 mg/day, and escitalopram was tapered off. Four weeks after the initiation of vortioxetine treatment, her depressive state gradually improved, and her HAM-D score decreased to 10. Her depressive state went into remission six weeks after treatment with vortioxetine, and her HAM-D score decreased to 4. During the treatment period, levodopa was sustained. Currently, she is doing well and continues to take levodopa (100 mg/day) and vortioxetine (20 mg/day). Worsening PD and depressive symptoms have not been observed.
**Discussion**

In the present case, vortioxetine successfully ameliorated the depressive symptoms of the PD patient who was resistant to paroxetine and escitalopram treatment. SSRIs, SNRIs, and TCAs have been the standard treatment for depression in patients with PD. Hence, while patients may not respond to one group of medications, they may respond to a different medication. However, several meta-analyses have suggested that the current evidence on the efficacy of TCAs and SSRIs in treating psychiatric symptoms is inconclusive [4-6,9-12]. TCAs are difficult to prescribe for presenile depression with PD because of their anticholinergic effects. Antidepressant-induced parkinsonism has been reported in patients treated with escitalopram and trazodone [13,14]. In contrast, another study suggested that SSRIs did not significantly worsen extrapyramidal symptomatology [15]. However, this needs further investigation. In the present case, SSRIs and SNRIs, including paroxetine, venlafaxine, escitalopram, and vortioxetine, did not worsen the patient’s parkinsonism. The exact mechanism of action of vortioxetine in improving the depressive symptoms of our patient remains unknown. A novel profile of vortioxetine for various serotonin receptors, including 5-HT$_{1A}$, 5-HT$_{1B}$, 5-HT$_{2A}$, and 5-HT$_{7}$, as well as serotonin transporters (5-HTT), is likely related to its clinical efficacy for ameliorating the depressive symptoms in PD patients. In short, vortioxetine is a 5-HT$_{7}$, 5-HT$_{1}$, and 5-HT$_{1A}$ receptor antagonist, 5-HT$_{1B}$ receptor partial agonist, 5-HT$_{1A}$ receptor agonist, and 5-HTT inhibitor [16]. It has been reported that the blockade of 5-HT$_{2}$ and 5-HT$_{3}$ receptors increase the release of dopamine [17]. Thus, it is plausible that the 5-HT$_{7}$ antagonistic effects of vortioxetine might also increase the release of dopamine. Another report suggested the enhanced release of dopamine, norepinephrine, acetylcholine, and histamine via several 5-HT$_{1A}$ and 5-HT$_{1B}$ receptors [18]. A recent post-marketing study in the world pharmacovigilance database [19] reported a potentially harmful association between movement disorders and the use of antidepressants, including mirtazapine, vortioxetine, amoxapine, fluvoxamine, citalopram, paroxetine, duloxetine, bupropion, clomipramine, escitalopram, fluoxetine, mianserin, sertraline, venlafaxine, and vilazodone. Another study demonstrated an association between SSRI use and apathy in PD patients [20]. Clinicians must be aware of these adverse effects and should continue to monitor their patients undergoing treatment. On the other hand, the multimodal antidepressant vortioxetine and the dual-action SNRIs, including venlafaxine, desvenlafaxine, and duloxetine, are considered to be good options for PD patients with depression [21].

**Conclusions**

We reported the case of a presenile female with PD suffering from depressive symptoms. Adding vortioxetine to her ongoing levodopa regimen resulted in the complete remission of her depressive symptoms without worsening PD, which was not contradictory to the recent expert opinion. This case indicated that vortioxetine is a viable treatment option for depression with severe anhedonia and psychomotor retardation in PD patients.

**Additional Information**

**Disclosures**

**Human subjects:** Consent was obtained or waived by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

**References**

1. Samii A, Nutt JG, Ransom BR: Parkinson’s disease. Lancet. 2004, 365:1783-95. 10.1016/S0140-6736(04)16305-8
2. Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF: A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord. 2008, 23:183-9. 10.1002/mds.21803
3. Ryan M, Eativon CV, Slevin JT: Drug treatment strategies for depression in Parkinson disease . Expert Opin Pharmacother. 2019, 20:1531-63. 10.1080/14656566.2019.1612877
4. Zhuo C, Xue R, Luo L, et al.: Efficacy of antidepressive medication for depression in Parkinson disease: a network meta-analysis. Medicine (Baltimore). 2017, 96:e6698. 10.1097/MD.0000000000006698
5. Mills KA, Greene MC, Dextube R, Goodson C, Karmarkar T, Pontone GM: Efficacy and tolerability of antidepressants in Parkinson’s disease: a systematic review and network meta-analysis. Int J Geriatr Psychiatry. 2018, 33:642-51. 10.1002/gps.4834
6. Skapinakis P, Bakola E, Salanti G, Lewis G, Kyritsis AP, Mavreas V: Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson’s disease: a systematic review and meta-analysis of randomized controlled trials. BMC Neurol. 2010, 10:49. 10.1186/1471-2377-10-49
7. Madhusoodanan S, Alexeenko L, Sanders R, Brenner R: Extrapyramidal symptoms associated with antidepressants—a review of the literature and an analysis of spontaneous reports. Ann Clin Psychiatry. 2010, 22:148-56.
8. Guo MF, Etminnan M, Procyslyn RM, Kim DD, Samii A, Kezouh A, Carleton BC: Association of antidepressant
use with drug-related extrapyramidal symptoms: a pharmacoepidemiological study. J Clin Psychopharmacol. 2018, 38:549–56. 10.1097/JCP.0000000000000911
9. Liu J, Dong J, Wang L, Su Y, Yan P, Sun S: Comparative efficacy and acceptability of antidepressants in Parkinson’s disease: a network meta-analysis. PLoS One. 2015, 8:e76651. 10.1371/journal.pone.0076651
10. Rocha FL, Murad MG, Stumpf BP, Hara C, Fuzikawa C: Antidepressants in depression in Parkinson’s disease: systematic review and meta-analysis. J Psychopharmacol. 2013, 27:417-23. 10.1177/0269881113478282
11. Troeung L, Egan S, Gasson N: A meta-analysis of randomised placebo-controlled treatment trials for depression and anxiety in Parkinson’s disease. PLoS One. 2013, 8:e79510. 10.1371/journal.pone.0079510
12. Takahashi M, Tabu H, Ozaki A, Hamano T, Takeshima T: Antidepressants for depression, apathy, and gait instability in Parkinson’s disease: a multicenter randomized study. Intern Med. 2019, 58:561-8. 10.2169/internalmedicine.1559-18
13. Ak S, Anıl Yağcıoğlu AE: Escitalopram-induced Parkinsonism. Gen Hosp Psychiatry. 2014, 36:e126.e1-2. 10.1016/j.genhosppsych.2013.09.010
14. Sarwar AI: Trazodone and Parkinsonism: the link strengthens. Clin Neuropharmacol. 2018, 41:106-8. 10.1097/WNF.0000000000000278
15. Dell’Agnello G, Ceravolo R, Nuti A, et al.: SSRIs do not worsen Parkinson’s disease: evidence from an open-label, prospective study. Clin Neuropharmacol. 2001, 24:221-7. 10.1097/00002826-200107000-00005
16. Sanchez C, Asin KE, Artigas F: Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther. 2015, 145:43-57. 10.1016/j.pharmthera.2014.07.001
17. Dolevíczenyi Z, Vizi ES, Gacsályi I, et al.: 5-HT6/7 receptor antagonists facilitate dopamine release in the cochlea via a GABAergic disinhibitory mechanism. Neurochem Res. 2008, 33:2646-72. 10.1007/s11064-008-9766-4
18. Stahl SM: Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): actions at serotonin receptors may enhance downstream release of four pro-cognitive neurotransmitters. CNS Spectr. 2015, 20:515-9. 10.1017/S1092852915000358
19. Revet A, Montastruc F, Rousin A, Raynaud JP, Lupeyre-Mestre M, Nguyen TTH: Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database. BMC Psychiatry. 2020, 20:508. 10.1186/s12888-020-02711-z
20. Zabodne LB, Bernal-Pacheco O, Bowers D, et al.: Are selective serotonin reuptake inhibitors associated with greater apathy in Parkinson’s disease? J Neuropsychiatry Clin Neurosci. 2012, 24:326-30. 10.1176/appi.neuropsych.11090210
21. Agüera-Ortiz L, García-Ramos R, Grandas Pérez FJ, et al.: Focus on depression in Parkinson’s disease: a Delphi consensus of experts in psychiatry, neurology, and geriatrics. Parkinsons Dis. 2021, 2021:6621991. 10.1155/2021/6621991